Compare · NRC vs PPD
NRC vs PPD
Side-by-side comparison of NRC Health (NRC) and PPD, Inc. (PPD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NRC and PPD operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- PPD is the larger of the two at $16.64B, about 42.5x NRC ($391.9M).
- NRC has hit the wire 2 times in the past 4 weeks while PPD has been quiet.
- PPD has more recent analyst coverage (1 ratings vs 0 for NRC).
- Company
- NRC Health
- PPD, Inc.
- Price
- $17.18-0.66%
- $47.29-0.07%
- Market cap
- $391.9M
- $16.64B
- 1M return
- +0.73%
- -
- 1Y return
- +59.12%
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 2
- 0
- Recent ratings
- 0
- 1
NRC Health
National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, health risk assessments, employee engagement, reputation management, and brand loyalty. The company also offers market insights solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient and resident experience, workforce engagement, health risk assessments, transitions, and improvement tools. Further, the company offers health risk assessment solutions that enable clients to segment populations and manage care for those who are most at risk, engage individuals, enhance preventative care, and manage wellness programs; and transitions solutions, which enable organizations to identify and manage high-risk patients to reduce readmissions, enhance patient satisfaction and support safe care transitions. Additionally, it provides transparency solutions that allow healthcare organizations to share picture of their organization and ensure content informs in consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. The company serves integrated health systems, post-acute providers, and payer organizations. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.
PPD, Inc.
PPD, Inc., together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company has a collaboration with Science 37 to design, build, test, implement, and execute digital trials using Science 37's DCT SaaS-based technology platform. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina.
Latest NRC
- National Research Corporation filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Ann & Robert H. Lurie Children's Hospital of Chicago Expands Partnership with NRC Health to Strengthen Consumer Insight and Online Reputation Strategy
- Amendment: SEC Form SCHEDULE 13D/A filed by National Research Corporation
- Piedmont Names NRC Health as a Strategic Experience Partner to Support Mission-Driven Growth
- Executive Vice President Rau Jason Russell was granted 60,000 shares (SEC Form 4)
- NRC Health Announces Board Authorization of $60 Million Share Repurchase Program
- SEC Form S-8 filed by National Research Corporation
- SEC Form 10-K filed by National Research Corporation
- NRC Health Provides Business Update
- EVP & Chief Financial Officer Harrison Shane R bought $98,162 worth of shares (8,000 units at $12.27) (SEC Form 4)
Latest PPD
- InnoCare Pharma Goes Back to Funding Trough With STAR Market Listing
- Saama Appoints Scott Rogers as Company's Chief Financial Officer
- SEC Form 15-12B filed by PPD, Inc.
- SEC Form 4: Carlyle Group Inc. disposed of $2,646,829,818 worth of shares (55,722,733 units at $47.50)
- SEC Form SC 13G filed by PPD, Inc.
- SEC Form 4: H&F Corporate Investors Viii, Ltd. sold $6,309,960,135 worth of shares (132,841,266 units at $47.50)
- SEC Form 4: H&F Corporate Investors Vii, Ltd. sold $6,309,960,135 worth of shares (132,841,266 units at $47.50)
- SEC Form 4: Johnston David Michael returned $1,681,832 worth of shares to the company (60,929 units at $27.60) and was granted 25,522 shares, closing all direct ownership in the company
- SEC Form 4: Hill Colin returned $775,675 worth of shares to the company (16,330 units at $47.50), closing all direct ownership in the company
- SEC Form 4: Kaucic Karen returned $398,620 worth of shares to the company (31,496 units at $12.66) and was granted 23,104 shares, closing all direct ownership in the company